The announcement came from the producer of Abdala vaccine. In June it was found to have a 92.28% efficacy.
Both vaccines are “low” tech, meaning they use a traditional approach deploying a part of the virus’s spike protein which helps the virus enter and infect cells, to build up the immune system.
These vaccines are generally less expensive to develop and easier to store and transport as they do not require extremely low temperatures.
While the Cuban efficacy claims have not been peer reviewed, the results, if accurate, would catapult the U.S.-boycotted Caribbean island nation into the select group of the United States, Germany and Russia that produce vaccines with efficacy of more than 90% - namely, Novavax, Pfizer-BioNTech, Moderna and Sputnik V.
Cuba says it has a total of five candidate vaccines in the pipeline, with Abdala and Soberana 2 expected to be quickly authorized for emergency use by local regulators and sent up for approval to the World Health Organization.
As it was reported earlier, Cuba is facing its worst COVID-19 outbreak since the start of the pandemic following the arrival of more contagious variants, setting new records for daily coronavirus cases at over 3,500 this week.